MAP2K7 and plasma cell myeloma: In case reports, heavily pretreated BRAF V600E-mutated multiple myeloma patients experienced durable responses with either the BRAF inhibitor vemurafenib alone and vemurafenib plus the MEK inhibitor cobimetinib and served as proof-of-concept for the efficacy of BRAF inhibition in multiple myeloma (13, 16).